UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 255,607 Shares of Baxter International Inc. $BAX

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in Baxter International Inc. (NYSE:BAX) by 14.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,513,888 shares of the medical instruments supplier’s stock after selling 255,607 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.29% of Baxter International worth $32,276,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. acquired a new stake in Baxter International during the second quarter worth approximately $1,744,874,000. Pzena Investment Management LLC bought a new stake in Baxter International in the 2nd quarter valued at $1,392,098,000. Geode Capital Management LLC increased its position in Baxter International by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 13,510,205 shares of the medical instruments supplier’s stock worth $257,174,000 after buying an additional 972,891 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of Baxter International by 1.3% during the second quarter. Ameriprise Financial Inc. now owns 7,638,629 shares of the medical instruments supplier’s stock worth $231,304,000 after buying an additional 97,687 shares in the last quarter. Finally, Equity Investment Corp acquired a new stake in shares of Baxter International during the second quarter worth $146,815,000. Institutional investors and hedge funds own 90.19% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on BAX. Wells Fargo & Company lifted their price objective on shares of Baxter International from $19.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Stifel Nicolaus lifted their price target on shares of Baxter International from $19.00 to $24.00 and gave the company a “hold” rating in a research report on Tuesday, July 28th. UBS Group increased their price target on Baxter International from $19.00 to $25.00 and gave the stock a “hold” rating in a research report on Tuesday, July 28th. Weiss Ratings upgraded Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Finally, Citigroup raised Baxter International from a “sell” rating to a “neutral” rating and lifted their price objective for the company from $17.00 to $28.00 in a report on Friday, July 31st. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $22.45.

Baxter International Stock Performance

Shares of NYSE:BAX opened at $25.53 on Friday. Baxter International Inc. has a 1 year low of $15.73 and a 1 year high of $30.00. The stock has a market capitalization of $13.20 billion, a price-to-earnings ratio of -12.33, a price-to-earnings-growth ratio of 3.89 and a beta of 0.60. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.95 and a quick ratio of 1.32. The company’s 50 day simple moving average is $24.65 and its 200 day simple moving average is $20.68.

Baxter International (NYSE:BAX) last issued its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The firm had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $2.80 billion. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.The company’s revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.59 EPS. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. As a group, research analysts predict that Baxter International Inc. will post 2.04 EPS for the current fiscal year.

Baxter International Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Friday, August 28th will be paid a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, August 28th. Baxter International’s payout ratio is currently -1.93%.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.